NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading VVOS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown volatility in management and performance, making it a higher-risk proposition.
The market seems to have priced in a low valuation compared to peers, reflecting a justified stance given the company's recent struggles. There is an expectations gap, indicating that investors may not expect significant improvements in the near term.
Management is focused on improving revenue growth, which has shown some progress. However, they are struggling to manage operating expenses effectively, leading to continued losses. The near-term risk of an earnings miss is elevated, as the company has a history of misses.
The future performance of VVOS will depend on its ability to meet or exceed guidance in upcoming earnings calls. Additionally, the performance of larger healthcare companies could influence VVOS's trajectory, either providing support or posing risks.
In the next 1 to 3 years, VVOS's success will largely depend on management's execution and sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The company is at risk of delisting due to low stock price. Staying compliant is crucial for operations.
Confirms:A press release says they meet Nasdaq's minimum bid price of $1.00 per share.
Disproves:A further notice of delisting or failure to meet compliance by the deadline.
Why it matters: Fixing compliance issues is key to keeping the Nasdaq listing. It impacts investor trust and stock stability.
Confirms one read:The company announces a plan that resolves the Nasdaq compliance issue by July.
Confirms the other:If no resolution is announced by July, it may lead to delisting.
Why it matters: An update on compliance will explain if Vivos can stay listed on Nasdaq.
Confirms:A statement confirms compliance with Nasdaq listing rules.
Disproves:Another notice of delisting or failure to meet compliance standards.
Why it matters: Approval gives Vivos the money it needs to support its operations and grow.
Confirms:The SEC says the registration statement for the rights offering is effective.
Disproves:The SEC does not approve the registration statement in the expected time.
Why it matters: Resolving compliance issues is crucial for Vivos to maintain its Nasdaq listing.
Confirms:Vivos confirms it meets Nasdaq listing rules.
Disproves:Vivos gets another notice of delisting from Nasdaq.
Why it matters: Controlling operating costs is important for better financial health. A drop shows good cost control.
Confirms:Operating expenses decline from $6.6M in Q1 to below $6.0M in Q2.
Disproves:Operating costs rise or stay above $6.6M in Q2.
Why it matters: Managing costs is key for better financial health. It helps the company grow.
Confirms:Operating costs are steady or lower than in previous quarters.
Disproves:Operating expenses are still rising. This makes financial losses worse.
Why it matters: New partnerships can drive growth and improve market position. This is a key management priority.
Confirms:There is news of more partnerships beyond the recent one with SPCVA.
Disproves:No new partnerships were announced. This shows slow growth efforts.
Why it matters: Strong revenue growth shows that Vivos is changing its business model successfully.
Confirms:Q2 revenue growth exceeds 20% year over year.
Disproves:Q2 revenue growth is below 10% year over year.
Why it matters: Launching AIM Florida would expand Vivos' reach in treating sleep apnea and insomnia.
Confirms:AIM Florida begins work with a full Sleep Optimization Team.
Disproves:AIM Florida's launch is delayed or canceled.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
